Journey Medical (FBIO) Q2 2026 Earnings Call: Revenue Rises 23% as Emrosi Accelerates
Source Tradingkey
Key Takeaways
- Second-quarter 2026 revenue increased 23% year over year to $18.5 million, primarily driven by Emrosi, which generated $8.1 million in net revenue.
- Emrosi prescriptions reached approximately 36,000, up 20% sequentially from about 30,000 in Q1 2026. July prescriptions subsequently rose to approximately 14,000 from 13,000 in June.
- GAAP net loss narrowed to $300,000, or $0.01 per share, from $3.8 million, or $0.16 per share, in Q2 2025. Adjusted EBITDA improved to positive $2.9 million.
- Emrosi’s unique prescriber base exceeded 4,500, up more than 40% from approximately 3,200 at the end of 2025. June new prescriptions reached a monthly record of more than 5,300.
- High-quality formulary coverage for Emrosi increased from 34% of commercial lives in Q1 to approximately 38%. Management expects reimbursement progress to support further ASP improvement in the second half of 2026.
- Journey Medical expects to remain EBITDA positive for the rest of 2026 and continues to describe the year as a potential breakout period for revenue growth and profitability.
Key Financial Data
| Metric | Q2 2026 | Q2 2025 | Change / Commentary |
|---|---|---|---|
| Total revenue | $18.5 million | $15.0 million | Up 23% year over year |
| Emrosi net revenue | $8.1 million | — | Main revenue growth driver |
| Gross margin | 67% | 67% | Unchanged year over year |
| SG&A expense | $10.9 million | $11.9 million | Lower due primarily to prior-year Emrosi launch spending |
| GAAP net loss | $0.3 million | $3.8 million | Loss narrowed materially |
| GAAP loss per share | $0.01 | $0.16 | Basic and diluted |
| EBITDA | $1.4 million | $(1.9) million | Turned positive |
| Adjusted EBITDA | $2.9 million | $(0.5) million | Turned positive |
| Cash | $25.6 million | $24.1 million at Dec. 31, 2025 | Increased by $1.5 million |
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Oil prices surged 5% following direct Israel-Iran strikes, while gold tumbled below $4,300 as a blowout U.S. jobs report fueled intense market anxieties over a December Federal Reserve rate hike.
XRP (XRP) price trades near $1.05, caught between a year-long downtrend and a sudden burst of buying.July has historically rewarded XRP holders. This year the month arrives with on-chain accumulation
On July 1, Eastern Time, U.S. stocks closed fluctuating lower on the first trading day of the second half of the year. Although some megacap tech stocks such as Meta (
Gold holds above $4,350 following weak US jobs data. As inflation reports approach and UBS eyes $5,000, can XAUUSD break resistance at $4,435 to rally toward $4,500?
Gold Price Analysis Today: Gold Drops 1.32% Despite Lower Fed Rate-Hike Bets, Can $4,313 Support Hold?
Gold fell 1.32% on August 13 after rising to $4,449.73, then reversing lower and closing near $4,349.918 below the $4,356.46 support. Softer US inflation data reduced Fed rate hike expectations, but selling pressure still dominated the session. Will $4,313 support hold?
Gold fell 1.32% on August 13 after rising to $4,449.73, then reversing lower and closing near $4,349.918 below the $4,356.46 support. Softer US inflation data reduced Fed rate hike expectations, but selling pressure still dominated the session. Will $4,313 support hold?
